Aquestive Therapeutics forecasts 2026 revenue USD 46 million-50 million
Reuters2026/08/12 15:21- Aquestive Therapeutics guided 2026 total revenue of about USD 46 million to USD 50 million.
- Forecast non-GAAP adjusted EBITDA loss of about USD 35 million to USD 30 million.
- Q2 2026 ended with about USD 98.5 million in cash and cash equivalents.
- Expects USD 75 million from the RTW Strategic Funding Agreement upon Anaphylm approval.
- Also anticipates USD 20 million in additional debt financing from Oak Tree upon Anaphylm approval.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Dogecoin ETF Closure Sets October Exit for Bitwise BWOW Holders
Crypto prices
More
